Christopher Broder Ph.D.

Education

1983 B.S., Biological Sciences, with honors. Florida Institute of Technology, Melbourne, Florida.
1985 M.S., Molecular Biology, Florida Institute of Technology, Melbourne, Florida.
1989 Ph.D., Microbiology and Immunology. College of Medicine, University of Florida, Gainesville, Florida.

Biography

Christopher C. Broder received his B.S. (1983) and M.S. (1985) degrees from the Florida Institute of Technology, Melbourne. He earned his Ph.D. from the University of Florida, Gainesville (1989) establishing a molecular-pathogenic model for the flesh-eating Group A streptococci. He began his postdoctoral studies in 1989 as a National Research Council Research Associate in the Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, focusing on HIV-1 host cell entry and infection. He joined the faculty of the Department of Microbiology and Immunology at Uniformed Services University (USU), Department of Defense (DoD), as Assistant Professor in 1996 and was promoted to Full Professor, tenured, in 2005. His laboratory has focused on virus-host cell interactions, virus receptor discovery, virus entry and virus-mediated membrane fusion, vaccines and antibody therapeutics development, and enveloped RNA virus surveillance. Research areas have included HIV-1 and emerging zoonotic viruses including Nipah virus and Hendra virus; Ebola and Marburg viruses, and bat lyssaviruses (rabies-like viruses). Dr. Broder’s major collaborative research contributions include the discoveries of the CXCR4 and the CCR5 HIV-1 coreceptors (1996-Breakthrough of the Year, Science magazine and the AAAS Newcomb Cleveland Prize 1997); the development of the first oligomeric, HIV-1 soluble gp140 glycoprotein vaccine candidate; discovery of the host cell entry receptor proteins (ephrin ligands) used by Nipah virus and Hendra virus; development of the Hendra/Nipah soluble-G glycoprotein (sG) subunit vaccines, and one formulation of HeV-sG is known as Equivac® HeV (Zoetis, Inc.) the first commercialized vaccine against a BSL-4 agent, for use in horses in Australia to prevent Hendra virus infection in horses and any subsequent infection in people – an example of the One-Health approach to counter important infectious diseases. Dr. Broder’s other translational research programs has led to the clinical development of the henipavirus sG subunit vaccine for Nipah virus and Hendra virus, and HeV-sG completed a Phase 1 clinical trial in 2022 supported by CEPI (The Coalition for Epidemic Preparedness Innovations). In addition, therapeutic antiviral human and humanized monoclonal antibodies (mAbs) have been collaboratively developed from his NIH and DoD funded research programs, including the anti-Hendra/Nipah human mAb m102.4, which to date has been used by emergency protocol in 18 people in Australia and one person in the U.S. because of significant risk of Hendra virus or Nipah virus infection, and mAb m102.4 completed a Phase 1 clinical trial in 2017 in Australia. A second anti-Hendra/Nipah mAb (MBP1F5) developed in collaboration with Mapp Biopharmaceutical, Inc., is currently in a Phase 1 trial in the U.S. and supported by the DoD, and mAb MBP1F5 has also been selected for additional Phase 1 clinical trials and evaluation outside the U.S. with support from CEPI. Dr. Broder’s honors include the 2013 and 2019 Federal Laboratory Consortium (FLC) Awards for Excellence in Technology Transfer and the 2020 FLC Impact Award; the CSIRO Chairman’s Medal for 2013, (Australia's national science agency); the 2014 Cinda Helke Award for Excellence in Graduate Student Advocacy; the 2008 Henry Wu Award for Excellence in Basic Science Research; the 2016 James J. Leonard Award for Excellence in Translational/Clinical Research; the Military Health System Research Symposium (MHSRS) 2020 Outstanding Individual Research Accomplishment Award; the MHSRS 2021 Outstanding Research Accomplishment Team Award; and the Carol Johns Medal (the highest USU faculty honor). He has mentored 13 graduate students and 15 postdoctoral fellows and scientists; coauthored more than 230 scientific articles and book chapters cited more 29,000 times; serves on the editorial board of five journals, and is an inventor on more than 30 US and foreign patents and/or licensed technologies. He also served as Director of the Emerging Infectious Diseases PhD Graduate Program at USU from 2006-2018, and is currently Professor and Chair of the Department of Microbiology and Immunology, USU.

Career Highlights: Positions, Projects, Deployements, Awards and Additional Publications

Laing ED, Mendenhall IH, Linster M, Low DHW, Chen Y, Yan L, Sterling SL, Borthwick S, Neves ES, Lim JSL, Skiles M, Lee BPY, Wang LF, Broder CC, Smith GJD. Serologic Evidence of Fruit Bat Exposure to Filoviruses, Singapore, 2011-2016. Emerg Infect Dis. 2018 Jan; 24(1):114-117. doi: 10.3201/eid2401.170401.

Li, Y, Wang, J, Hickey, AC, Zhang, Y, Li, Y, Wu, Y., Zhang, H, Yuan, J, Han, Z, McEachern, J, Broder, CC, Wang, LF, Shi, Z. Antibodies to Nipah or Nipah-like viruses in bats, China. Emerg Infect Dis. 14(12):1974-6 2008.

Chowdhury S, Khan SU, Crameri G, Epstein JH, Broder CC, Islam A, Peel AJ, Barr J, Daszak P, Wang LF, Luby SP. Serological evidence of henipavirus exposure in cattle, goats and pigs in Bangladesh. PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3302. doi: 10.1371/journal.pntd.0003302. 2014 Nov.

Xu K, Rockx B, Xie Y, DeBuysscher BL, Fusco DL, Zhu Z, Chan YP, Feldmann H, Dimitrov DS, Broder CC, and Nikolov DB. Crystal structure of the Hendra virus attachment G glycoprotein complexed with a potent cross-reactive neutralizing human monoclonal antibody. Plos Pathogens, 2013 Oct;9(10):e1003684.

Xu K, Chan YP, Bradel-Tretheway B, Akyol-Ataman Z, Zhu Y, Dutta S, Yan L, Feng YR, Wang LF, Skiniotis G, Lee B, Zhou ZH, Broder CC*, Aguilar HC* and Nikolov DB*. Crystal structure of the pre-fusion Nipah virus fusion glycoprotein reveals a novel hexamer-of-trimers assembly. PLoS Pathog. 2015 Dec 8;11(12):e1005322. doi: 10.1371/journal.ppat.1005322

Dang HV, Cross RW, Borisevich V, Bornholdt ZA, West BR, Chan YP, Mire CE, Da Silva SC, Dimitrov AS, Yan L, Amaya M, Navaratnarajah CK, Zeitlin L, Geisbert TW, Broder CC, Veesler D. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nat Struct Mol Biol. 2021 May;28(5):426-434. doi: 10.1038/s41594-021-00584-8

Wang Z, Amaya M, Addetia A, Dang HV, Reggiano G, Yan L, Hickey AC, DiMaio F, Broder CC, Veesler D. Architecture and antigenicity of the Nipah virus attachment glycoprotein. Science. 2022 Mar 25;375(6587):1373-1378. DOI: 10.1126/science.abm5561

Wang Z, Dang HV, Amaya M, Xu Y, Yin R, Yan L, Hickey AC, Annand EJ, Horsburgh BA, Reid PA, Smith I, Eden JS, Xu K, Broder CC, Veesler D. Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant. Proc Natl Acad Sci U S A. 2022 May 31;119(22):e2122769119. doi: 10.1073/pnas.2122769119.

Laing, ED, Navaratnarajah, CK, Cheliout Da Silva, S, Petzing, SR, Xu, Y, Sterling, SL, Marsh, GA, Wang, LF, Amaya, M, Nikolov, DB, Cattaneo R, Broder, CC*, and Xu, K. Structural and Functional Analyses Reveal Promiscuous and Species-Specific Use of Ephrin Receptors by Cedar Virus. Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20707-20715.

Amaya M, Cheng H, Borisevich V, Navaratnarajah CK, Cattaneo R, Cooper L, Moore TW, Gaisina IN, Geisbert TW, Rong L, Broder CC. A recombinant Cedar virus based high-throughput screening assay for henipavirus antiviral discovery. Antiviral Res. 2021 May 30:105084.

Representative Bibliography

Broder, CC, PL Earl, D Long, B Moss, and RW Doms. Antigenic Implications of HIV-1 Envelope Glycoprotein Quaternary Structure: Oligomer-Specific and -Sensitive mAbs. Proc. Natl. Acad. Sci. USA. 91:11699-11703, 1994.

Broder, CC and EA Berger. Fusogenic Selectivity of the Envelope Glycoprotein is a Major Determinant of HIV-1 Tropism for CD4+ T-Cell Lines vs. Macrophages. Proc. Natl. Acad. Sci. USA. 92:9004-08, 1995.

Feng, Y, CC Broder, PE Kennedy, and EA Berger. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor. Science. 272:872-877, 1996.

Bonaparte, MI, AS Dimitrov, KN Bossart, G Crameri, BA Mungall, KA Bishop, V Choudhry, DS Dimitrov, LF Wang, BT Eaton, and CC Broder*. Ephrin-B2 Ligand is a Functional Receptor for Hendra Virus and Nipah Virus. Proc Natl Acad Sci U S A. 102(30):10652-7. 2005. (from the cover)

Bossart, KN, Zhu Z, Middleton, D, Klippel, J, Crameri, G, Bingham, J, McEachern, JA, Green, D, Hancock, TJ, Chan, YP, Hickey, AC, Dimitrov, DS, Wang, LF, Broder, CC. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. Plos Pathogens. 2009 Oct;5(10):e1000642.

Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, Lacasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC*, Feldmann H, Geisbert TW. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med. 4(146):146ra107. 2012

Middleton D, Pallister J, Klein R, Feng YR, Haining J, Arkinstall R, Frazer L, Huang JA, Edwards N, Wareing M, Elhay M, Hashmi Z, Bingham J, Yamada M, Johnson D, White J, Foord A, Heine HG, Marsh GA, Broder CC, Wang LF. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis. 2014 Mar;20(3).

Geisbert TW, Mire CE, Geisbert JB, Chan YP, Agans KN, Feldmann F, Fenton KA, Zhu Z, Dimitrov DS, Scott DP, Bossart KN, Feldmann H, Broder CC*. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med. 2014, 6(242):242ra82.

Geisbert TW, Bobb K, Borisevich V, Geisbert JB, Agans KN, Cross RW, Prasad AN, Fenton KA, Yu H, Fouts TR, Broder CC, Dimitrov AS. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus. NPJ Vaccines. 2021 Feb 8;6(1):23.DOI: 10.1038/s41541-021-00284-w

Zeitlin L, Cross RW, Woolsey C, West BR, Borisevich V, Agans KN, Prasad AN, Deer DJ, Stuart L, McCavitt-Malvido M, Kim DH, Pettitt J, Crowe JE Jr, Whaley KJ, Veesler D, Dimitrov A, Abelson DM, Geisbert TW, Broder CC. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates. Sci Transl Med. 2024 Apr 3;16(741):eadl2055. doi: 10.1126/scitranslmed.adl2055